RedHill Biopharma Ltd. (NASDAQ:RDHL) – Analysts at Roth Capital cut their FY2018 EPS estimates for shares of RedHill Biopharma in a research report issued on Monday. Roth Capital analyst S. Henry now forecasts that the brokerage will post earnings per share of ($2.00) for the year, down from their previous forecast of ($1.60).

Several other research firms also recently commented on RDHL. FBR & Co reaffirmed an “outperform” rating and issued a $36.00 target price on shares of RedHill Biopharma in a research report on Wednesday. Zacks Investment Research raised RedHill Biopharma from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research report on Tuesday, June 28th. Finally, HC Wainwright set a $33.00 target price on RedHill Biopharma and gave the company a “buy” rating in a research report on Friday, October 7th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $26.20.

RedHill Biopharma (NASDAQ:RDHL) traded down 3.63% during midday trading on Wednesday, hitting $13.53. The stock had a trading volume of 52,852 shares. The company has a 50-day moving average of $14.57 and a 200-day moving average of $12.83. RedHill Biopharma has a 1-year low of $8.10 and a 1-year high of $16.54. The stock’s market cap is $172.29 million.

RedHill Biopharma (NASDAQ:RDHL) last released its quarterly earnings results on Wednesday, July 27th. The company reported ($0.06) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.58) by $0.52.

Several large investors have recently modified their holdings of the stock. Ingalls & Snyder LLC bought a new stake in shares of RedHill Biopharma during the second quarter valued at about $451,000. Royal Bank of Canada boosted its stake in RedHill Biopharma by 0.9% in the first quarter. Royal Bank of Canada now owns 21,167 shares of the company’s stock valued at $259,000 after buying an additional 191 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new stake in RedHill Biopharma during the second quarter valued at $142,000. Finally, Van ECK Associates Corp boosted its stake in RedHill Biopharma by 1.5% in the second quarter. Van ECK Associates Corp now owns 9,623 shares of the company’s stock valued at $105,000 after buying an additional 138 shares during the last quarter. Institutional investors and hedge funds own 15.30% of the company’s stock.

RedHill Biopharma Company Profile

5 Day Chart for NASDAQ:RDHL

Receive News & Stock Ratings for RedHill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma Ltd. and related stocks with our FREE daily email newsletter.